Does the media refer more to NTRA or HALO?

In the previous week, Natera had 15 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 30 mentions for Natera and 15 mentions for Halozyme Therapeutics. Natera's average media sentiment score of 1.34 beat Halozyme Therapeutics' score of 1.04 indicating that Natera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natera 25 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Halozyme Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RVMD or HALO?

In the previous week, Halozyme Therapeutics had 3 more articles in the media than Revolution Medicines. MarketBeat recorded 15 mentions for Halozyme Therapeutics and 12 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 1.37 beat Halozyme Therapeutics' score of 1.04 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Halozyme Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer HALO or BIIB?

In the previous week, Biogen had 13 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 28 mentions for Biogen and 15 mentions for Halozyme Therapeutics. Biogen's average media sentiment score of 1.35 beat Halozyme Therapeutics' score of 1.04 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 22 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ALNY or HALO?

In the previous week, Alnylam Pharmaceuticals had 10 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 25 mentions for Alnylam Pharmaceuticals and 15 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.04 beat Alnylam Pharmaceuticals' score of 0.81 indicating that Halozyme Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 11 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Halozyme Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Halozyme Therapeutics (HALO) Competitors

$108.17 +2.05 (+1.93%)

As of 08/21/2026 04:00 PM Eastern

Compare

HALO vs. NTRA, RVMD, BIIB, ALNY, and INSM

Should you buy Halozyme Therapeutics stock or one of its competitors? Halozyme Therapeutics's main competitors and comparable companies include Natera (NTRA), Revolution Medicines (RVMD), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), and Insmed (INSM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Halozyme Therapeutics compare to Natera?

Natera (NASDAQ:NTRA) and Halozyme Therapeutics (NASDAQ:HALO) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

99.9% of Natera shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 5.1% of Natera shares are owned by insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Natera presently has a consensus price target of $319.38, suggesting a potential downside of 3.81%. Halozyme Therapeutics has a consensus price target of $91.20, suggesting a potential downside of 15.69%. Given Natera's stronger consensus rating and higher possible upside, equities analysts plainly believe Natera is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	1 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.82
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

Halozyme Therapeutics has a net margin of 24.86% compared to Natera's net margin of -7.11%. Halozyme Therapeutics' return on equity of 260.98% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-7.11%	-11.38%	-7.87%
Halozyme Therapeutics	24.86%	260.98%	23.91%

Halozyme Therapeutics has lower revenue, but higher earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31B	20.75	-$208.16M	-$1.36	N/A
Halozyme Therapeutics	$1.66B	7.38	$316.89M	$3.35	32.29

Natera has a beta of 1.51, meaning that its share price is 51% more volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market.

In the previous week, Natera had 15 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 30 mentions for Natera and 15 mentions for Halozyme Therapeutics. Natera's average media sentiment score of 1.34 beat Halozyme Therapeutics' score of 1.04 indicating that Natera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natera	25 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Halozyme Therapeutics	10 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Natera beats Halozyme Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Halozyme Therapeutics compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Halozyme Therapeutics (NASDAQ:HALO) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Revolution Medicines currently has a consensus price target of $167.89, suggesting a potential downside of 19.85%. Halozyme Therapeutics has a consensus price target of $91.20, suggesting a potential downside of 15.69%. Given Halozyme Therapeutics' higher probable upside, analysts plainly believe Halozyme Therapeutics is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

Revolution Medicines has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market.

Halozyme Therapeutics has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,877.00	-$1.13B	-$8.82	N/A
Halozyme Therapeutics	$1.66B	7.38	$316.89M	$3.35	32.29

Halozyme Therapeutics has a net margin of 24.86% compared to Revolution Medicines' net margin of 0.00%. Halozyme Therapeutics' return on equity of 260.98% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Halozyme Therapeutics	24.86%	260.98%	23.91%

In the previous week, Halozyme Therapeutics had 3 more articles in the media than Revolution Medicines. MarketBeat recorded 15 mentions for Halozyme Therapeutics and 12 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 1.37 beat Halozyme Therapeutics' score of 1.04 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Halozyme Therapeutics	10 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Halozyme Therapeutics beats Revolution Medicines on 10 of the 17 factors compared between the two stocks.

How does Halozyme Therapeutics compare to Biogen?

Halozyme Therapeutics (NASDAQ:HALO) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Halozyme Therapeutics has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, suggesting that its stock price is 83% less volatile than the broader market.

Biogen has higher revenue and earnings than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.66B	7.38	$316.89M	$3.35	32.29
Biogen	$10.03B	3.19	$1.29B	$5.65	38.37

Halozyme Therapeutics has a net margin of 24.86% compared to Biogen's net margin of 8.32%. Halozyme Therapeutics' return on equity of 260.98% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
Biogen	8.32%	11.18%	6.88%

In the previous week, Biogen had 13 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 28 mentions for Biogen and 15 mentions for Halozyme Therapeutics. Biogen's average media sentiment score of 1.35 beat Halozyme Therapeutics' score of 1.04 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	10 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	22 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 2.5% of Halozyme Therapeutics shares are owned by company insiders. Comparatively, 0.3% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Halozyme Therapeutics currently has a consensus target price of $91.20, suggesting a potential downside of 15.69%. Biogen has a consensus target price of $227.07, suggesting a potential upside of 4.75%. Given Biogen's higher probable upside, analysts plainly believe Biogen is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

Summary

Biogen beats Halozyme Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Halozyme Therapeutics compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Halozyme Therapeutics (NASDAQ:HALO) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Halozyme Therapeutics has lower revenue, but higher earnings than Alnylam Pharmaceuticals. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$4.80B	6.58	$313.75M	$5.38	43.91
Halozyme Therapeutics	$1.66B	7.38	$316.89M	$3.35	32.29

In the previous week, Alnylam Pharmaceuticals had 10 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 25 mentions for Alnylam Pharmaceuticals and 15 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.04 beat Alnylam Pharmaceuticals' score of 0.81 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	11 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Halozyme Therapeutics	10 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Halozyme Therapeutics has a net margin of 24.86% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Halozyme Therapeutics' return on equity of 260.98% beat Alnylam Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Halozyme Therapeutics	24.86%	260.98%	23.91%

Alnylam Pharmaceuticals presently has a consensus price target of $386.62, suggesting a potential upside of 63.67%. Halozyme Therapeutics has a consensus price target of $91.20, suggesting a potential downside of 15.69%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Alnylam Pharmaceuticals is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	2.96
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

Alnylam Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

Summary

Halozyme Therapeutics beats Alnylam Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Halozyme Therapeutics compare to Insmed?

Halozyme Therapeutics (NASDAQ:HALO) and Insmed (NASDAQ:INSM) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

Halozyme Therapeutics presently has a consensus target price of $91.20, suggesting a potential downside of 15.69%. Insmed has a consensus target price of $205.52, suggesting a potential upside of 63.41%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

Halozyme Therapeutics has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market. Comparatively, Insmed has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

Halozyme Therapeutics has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.66B	7.38	$316.89M	$3.35	32.29
Insmed	$606.42M	45.29	-$1.28B	-$4.11	N/A

97.8% of Halozyme Therapeutics shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by company insiders. Comparatively, 2.1% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Halozyme Therapeutics had 15 more articles in the media than Insmed. MarketBeat recorded 15 mentions for Halozyme Therapeutics and 0 mentions for Insmed. Insmed's average media sentiment score of 1.84 beat Halozyme Therapeutics' score of 1.04 indicating that Insmed is being referred to more favorably in the news media.

Company	Overall Sentiment
Halozyme Therapeutics	Positive
Insmed	Very Positive

Halozyme Therapeutics has a net margin of 24.86% compared to Insmed's net margin of -76.94%. Halozyme Therapeutics' return on equity of 260.98% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
Insmed	-76.94%	-123.94%	-44.30%

Summary

Halozyme Therapeutics beats Insmed on 11 of the 17 factors compared between the two stocks.

Get Halozyme Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HALO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HALO vs. The Competition

Export

Metric	Halozyme Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.28B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	32.29	11.62	272.60	24.24
Price / Sales	7.38	1,338.17	618.96	99.78
Price / Cash	22.67	105.14	78.62	53.99
Price / Book	85.85	16.80	13.05	6.20
Net Income	$316.89M	-$12.50M	$3.47B	$348.59M
7 Day Performance	9.64%	3.29%	2.09%	0.08%
1 Month Performance	33.81%	8.23%	6.64%	3.88%
1 Year Performance	50.61%	55.05%	25.02%	16.98%

Halozyme Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HALO Halozyme Therapeutics	3.8838 of 5 stars	$108.17 +1.9%	$91.20 -15.7%	+50.6%	$12.28B	$1.66B	32.29	390	Positive News Insider Trade
NTRA Natera	2.5905 of 5 stars	$314.18 +1.4%	$319.38 +1.7%	+100.5%	$44.67B	$2.31B	N/A	6,140	News Coverage Positive News
RVMD Revolution Medicines	2.5369 of 5 stars	$212.00 +4.1%	$166.33 -21.5%	+466.0%	$43.66B	$11.58M	N/A	250	Positive News Analyst Forecast
BIIB Biogen	3.9629 of 5 stars	$209.15 -0.3%	$227.07 +8.6%	+55.6%	$31.00B	$9.89B	37.02	7,500	News Coverage Positive News
ALNY Alnylam Pharmaceuticals	4.9363 of 5 stars	$224.60 -1.8%	$393.86 +75.4%	-48.0%	$30.60B	$3.71B	41.75	2,770	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HALO) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Halozyme Therapeutics (HALO) Competitors

HALO vs. NTRA, RVMD, BIIB, ALNY, and INSM

How does Halozyme Therapeutics compare to Natera?

Summary

How does Halozyme Therapeutics compare to Revolution Medicines?

Summary

How does Halozyme Therapeutics compare to Biogen?

Summary

How does Halozyme Therapeutics compare to Alnylam Pharmaceuticals?

Summary

How does Halozyme Therapeutics compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HALO vs. The Competition

Halozyme Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Halozyme Therapeutics (HALO) Competitors

HALO vs. NTRA, RVMD, BIIB, ALNY, and INSM

How does Halozyme Therapeutics compare to Natera?

Do insiders & institutionals hold more shares of NTRA or HALO?

Do analysts prefer NTRA or HALO?

Is NTRA or HALO more profitable?

Which has better earnings and valuation, NTRA or HALO?

Which has more risk & volatility, NTRA or HALO?

Does the media refer more to NTRA or HALO?

Summary

How does Halozyme Therapeutics compare to Revolution Medicines?

Do insiders and institutionals hold more shares of RVMD or HALO?

Do analysts rate RVMD or HALO?

Which has more risk & volatility, RVMD or HALO?

Which has higher valuation & earnings, RVMD or HALO?

Is RVMD or HALO more profitable?

Does the media favor RVMD or HALO?

Summary

How does Halozyme Therapeutics compare to Biogen?

Which has more volatility & risk, HALO or BIIB?

Which has better valuation & earnings, HALO or BIIB?

Is HALO or BIIB more profitable?

Does the media prefer HALO or BIIB?

Do insiders & institutionals hold more shares of HALO or BIIB?

Do analysts recommend HALO or BIIB?

Summary

How does Halozyme Therapeutics compare to Alnylam Pharmaceuticals?

Do insiders & institutionals hold more shares of ALNY or HALO?

Which has preferable earnings & valuation, ALNY or HALO?

Does the media prefer ALNY or HALO?

Is ALNY or HALO more profitable?

Do analysts rate ALNY or HALO?

Which has more volatility and risk, ALNY or HALO?

Summary

How does Halozyme Therapeutics compare to Insmed?

Do analysts recommend HALO or INSM?

Which has more risk & volatility, HALO or INSM?

Which has better earnings and valuation, HALO or INSM?

Do institutionals and insiders have more ownership in HALO or INSM?

Does the media prefer HALO or INSM?

Is HALO or INSM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HALO vs. The Competition

Halozyme Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools